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The eosinophil chemotactic factor of anaphylaxis, ECF-A, 1 was discovered in 
1971 as a mediator released during immediate-type  hypersensitivity reactions in 
guinea pig (1) and human (2) lung slices. ECF-A was subsequently established 
as a totally preformed mediator in human nasal polyps (3) and lung fragments 
(4), and its association with tissue mast cells was demonstrated by extraction 
from dispersed human lung mast  cells  after  their  isopycnic and  isokinetic 
purification (5). The mast cell subcellular localization of this preformed media- 
tor was established by its isolation from purified rat peritoneal mast cells where 
it was contained in the granules (4). ECF-A released by IgE-mediated immuno- 
logic mechanisms (2, 4) had a mol wt of 500 and elicited preferential eosinophil 
chemotaxis, and a  principle with these characteristics was therefore isolated 
from among the various activities present in human lung extracts (6, 7). 
After extraction from human lung, sequential purification of this low mol wt 
eosinophilotactic activity  by  Sephadex  G-25,  Dowex-1,  Sephadex  G-10,  and 
paper chromatography led to the identification of  two acidic peptides of sequence 
Ala-Gly-Ser-Glu and Val-Gly-Ser-Glu in the active fractions (6). Both purified 
native and synthetic peptides were preferentially chemotactic for eosinophils in 
vitro in a Boyden chamber assay with peak activity at concentrations of 5 × 10  -s 
M to 10  -6 M in the stimulus compartment (6). The eosinophil chemotactic activ- 
ity of the synthetic peptides required a concentration gradient, elicited a wave of 
movement  of eosinophils into the micropore filters (7), and was dependent on the 
integrity of the NH~-terminal and COOH-terminal residues (6). The structural 
requirements for  chemotactic activity  of ECF-A  have  been further defined 
utilizing synthetic peptide analogues and substituents. A model of interaction 
between the tetrapeptide factor and eosinophil surface is proposed in which full 
eosinophil chemotactic activity is dependent on reversible interaction with the 
NH~-terminal residue and activation by the COOH-terminal residue. 
* Supported by grants AI-07722, AI-10356, HL-19777, and HL-17382 from the National Institutes 
of Health. 
$ Investigator and Director of the Laboratories for the Study of Immunologic Diseases, Howard 
Hughes Medical Institute. 
' Abbreviations used in this paper: ECF-A, eosinophil chemotactic factor of anaphylaxis; HBSS, 
Hanks' balanced salt solution; hpf, high power field. 
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Materials and Methods 
Dowex AG-1-XS, 200-400 mesh,  and Bio-Beads  S-X1 chloromethylated resin, 200-400 mesh 
(Bio-Rad Laboratories, Richmond, Calif.),  Sephadex G-10, Ficol] and dextran (Pharmacia Fine 
Chemicals, Inc., Piscataway, N. J.), sodium diatrizoate (Hypaque, Winthrop Laboratories, New 
York),  hydroxyl apatite  (Clarkson Chemical Co.,  Inc.,  Williamsport, Pa.),  diethylaminoethyl 
cellulose (DE-52) (Whatman Chemicals, Balston, Maidstone, Kent, England), Hanks' balanced 
salt solution (Microbiological  Associates,  Inc., Bethesda, Md.), ovalbumin five-times recrystal- 
lized (Miles Laboratories Inc., Elkhart, Ind.), anhydrous trifluoroacetic acid (redistilled in vacuo) 
(Eastman Kodak Co., Rochester,  N. Y.), alanine amide, valine amide, and leucine amide (Nutri- 
tional Biochemicals Corp.,  Cleveland, Ohio),  t-butoxycarbonyl (BOC)-amino  acids  (Beckman 
Instruments, Inc., Palo Alto, Calif.), N,N'-diisopropylethylamine (Matheson, Coleman & Bell, 
East Rutherford, N. J.), disposable polystyrene modified Boyden chambers (Adaps, Inc., Dedham, 
Mass.),  and twice-recrystallized trypsin previously treated  with diphenyl carbamyl chloride 
(Sigma Chemical Company, St.  Louis,  Mo.) were obtained as noted. All solvents were either 
Eastman Kodak Co. reagent grade or Fisher-certified (Fisher Scientific Co., Pittsburgh, Pa.) and 
were redistilled before use. Methylene chloride (CH2Clz) was further purified by passage through a 
column of alumina (Alumina Adsorption, Fisher Scientific Co.). N~'-dimethylformamide was 
filtered over a column of 4A molecular sieves (Matheson, Coleman & Bell) and stored with flesh 
sieves for 72 h before use (8). C5a was prepared by tryptic digestion (9, 10) of purified C5 prepared 
from human plasma (11). C5a-containing digestion mixtures were heated for 20 rain at 61°C to 
inactivate residual trypsin and then centrifuged to remove heat-precipitated proteins (10). 
Peptide Synthesis  and Purification.  Reaction vessels,  wrist-action shakers,  scrubbing and 
cleaving bottles, and other accessories for manual solid phase synthesis ofpeptides were obtained 
from Schwarz/Mann, Orangeburg, N. Y. For each tetrapeptide and tripeptide, 5 g of chloromethyl- 
ated resin (0.89 mmol of chloride per g) were reacted for 24 h at 37°C in dimethylformamide  with a 
twofold molar excess of the cesium salt of the BOC-derivative of the COOH-terminal residue (12). 
Subsequent  BOC-amino acid residues were successively  coupled to each deprotected NH2-terminus 
during a 12-h reaction interval at room temperature and with threefold molar excess both of the 
next amino acid  and dicyclohexyl  carbodiimide in CH~Clz (12). Each cycle was performed  by a 
standard procedure (12, 13) modified such that deprotection was accomplished with 25% (vol/vol) 
trifluoroacetic acid-CH2C12  for 30 min and washings, after deprotection, were carried out with 33% 
(vol/vol) dioxane in CH2Cl~ in alternate washes with CHIC12 (6). The completeness ofdeprotection 
and coupling in each cycle was assessed by determinations of total resin-associated amine with 
sequential chloride titrations (14). After the last coupling step, each peptide was cleaved from the 
resin with hydrogen bromide-trifluoroacetic  acid (12). All crude peptide preparations were freed of 
volatile contaminants  by stepwise addition and evaporation of three 80-ml portions each of CH2C12, 
ethanol, 0.1 M acetic acid, and water, respectively. Peptides were then dissolved in 2 ml of ethanol- 
0.1 M NH4OH (1:1, vol/vol) and filtered on Sephadex G-10 equilibrated in 0.1 M NH~OH. The 
peptide peaks, identified by the optical density at 215 nm of their peptide bonds, were pooled and 
lyophilized. The four tripeptides Ala]Leu/Phe/Val-Gly-Ser  were each redissolved in 0.1 M NH4OH, 
filtered  again on Sephadex  G-10, and pooled;  a  portion was  removed for analysis, and  the 
remainder was lyophilized.  The tetrapeptides and the COOH-terminal tripeptide, Gly-Ser-Glu, 
were each purified by elution from Dowex-1 in a pyridine-formic  acid gradient (6) and then filtered 
on Sephadex G-10 and further processed as described for the NH2-terminal tripeptides. The purity 
of each peptide preparation was confirmed by comparing its amino acid composition before and 
after an additional descending paper chromatography step (6). Amino acid analyses of 6N HC1 
hydrolysates were conducted according to Spackman et al.  (15) with a  Beckman model 120C 
automated analyzer. 
Leukocyte Migration.  Blood from normal donors or patients with peripheral blood hypereosin- 
ophilia of 26-89% was incubated for 30 min at 37°C with citrate anticoagulant and dextran to 
sediment erythrocytes (16). The leukocyte-rich supernatant plasma was aspirated and centrifuged 
at 100g for 10 rain at room temperature. The leukocyte pellet from hypereosinophilic  patients was 
washed three times and resuspended in Hanks' balanced salt solution made 0.4% in ovalbumin 
and 0.005 M in Tris-HC1 pH 7.4 (HBSS-ovalbumin)  for use in chemotactic assays. Neutrophils and 
mononuclear leukocytes, obtained by centrifugation on Ficoll-Hypaque (17) of the mixed leuko- 
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cell  suspensions were within  a range  of  concentrations  of  2,2  _+  0.5 × I@ eosinophils  per  ml, 2.0  +_ 
0.5 × 10  e  neutrophils  per  ml, and  3.0  _+  0.5 × 106  mononuclear  leukocytes  per  ml. i  ml  of  leukocyte 
suspension was employed in  the cell  compartment of  each  modified (16)  Boyden (18)  chemotactic 
chamber. A micropore  filter  of  3-~m pore size  for  eosinophils  and  neutrophils  and 8-~m pore  size 
for  mononuclear leukocytes separated the cells  in  the upper  compartment from the chemotactic 
stimuli  contained in 1 ml of  HBSS-ovalbumin in  the lower  compartment (2, 6). After a 21/2-3  h 
incubation period at 37°C,  the filters  were fixed,  removed from the disposable chambers, and 
stained (1).  Duplicate filters  from chambers  without  a stimulus  were used  to  determine  the depth 
within  the  filters  which  offered  a suitable  background of  2-8  leukocytes/high  power  field  (hpf)  for 
that experiment, and all  filters  from stimulated and control  chambers were read at this  depth 
without  knowledge of  the experimental  protocol.  Leukocytes  that migrated into  the filters  to  this 
standard level  were counted in 10 hpf, 5 from each of  duplicate  chambers, and the chemotactic 
responses were expressed as net leukocytes/hpf  after  correction  for  background counts.  In some 
protocols,  factors  were added  to  the  cell  compartment  or  were  used  to  pretreat  leukocytes,  and  the 
cells  were washed; the migration of  such cells  was determined as above and was expressed as a 
percent of  the response of  untreated leukocytes. 
Results 
Eosinophilotactic Activity of Analogues with NH2-Terminal Residue Substi- 
tutions or Internal Amino Acid Inversion or Deletion.  The dose responses of 
the chemotactic activity of synthetic tetrapeptides in which the NH2-terminal 
residue was Ala, Val, Leu, or Phe, and the common COOH-terminal tripeptide 
was Gly-Ser-Glu were compared (Fig. 1). Eosinophils were obtained from three 
separate donors, and the mean responses are depicted. Valyl-tetrapeptide was 
consistently more active than the alanyl-tetrapeptide, with their peak responses 
occurring at 3 ×  10  -7 M and 10  -6 M, respectively. The peak chemotactic activity 
for the  leucyl-tetrapeptide  was  achieved  at  10  -8  M,  while  the  phenylalanyl- 
tetrapeptide required 10  -4 M for peak effect. 
The dependence of eosinophil chemotactic activity on the spacing between the 
NH2- and  COOH-terminal  amino  acids and  on the  order of the  two internal 
residues  was  assessed  for  both  the  ECF-A  valyl-tetrapeptide  and  the  NH2- 
terminal  analogue leucyl-tetrapeptide series.  Inversion of the order of glycine 
and serine did not change the maximum eosinophil chemotactic activity or dose- 
response characteristics of either the valyl- or leucyl-tetrapeptides (Fig. 2). The 
condensed tripeptides, lacking glycine, required 10  -6 M for a maximum activity 
which  was  approximately  two-thirds  of the  maximum  chemotactic  activity 
obtained with the 10  -7 M concentrations of tetrapeptides. 
Chemotactic Deactivation and Cross-Deactivation of  Eosinophils.  Functional 
deactivation refers to the failure of a leukocyte to migrate along a concentration 
gradient of a  chemotactic stimulus as a  result of previous interaction  with an 
active chemotactic factor. Deactivation has the same specificity as chemotactic 
activation but differs in that the concentrations  of the factor interacting  with 
the target cell are defined beacuse a  gradient is not involved.  8  ×  l0  s human 
eosinophils were preincubated for 2-40 min at 37°C with varying doses of valyl- 
or alanyl-tetrapeptide  and washed three times with HBSS-ovalbumin. Deacti- 
vation is expressed as the percent residual  chemotactic responsiveness of the 
eosinophils to 10  -7 M valyl-tetrapeptide or C5a as compared to that of the un- 
treated cells. Deactivation of the eosinophils by both the alanyl- and the valyl- 
tetrapeptides to a subsequent valyl-tetrapeptide chemotactic stimulus was rapid 
and dose related.  Full deactivation was achieved by 10  -l°  M  alanyl-  or valyl- E.  J.  GOETZL  AND  K.  F.  AUSTEN 
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FIG.  1.  Eosinophil chemotactic activity  of ECF-A tetrapeptides  and NH2-terminal ana- 
logues. Values depicted are the mean -+ 1 SD for three experiments with unpurified eosino- 
phils from donors with 32, 56, and 89% peripheral  blood eosinophilia. 
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FIG.  2.  Eosinophil chemotactic activity of  analogues with internal amino acid inversion or 
deletion. Values shown are the mean of two experiments with unpurified eosinophils from 
donors with 38 and 76% eosinophilia. 
tetrapeptide (Fig. 3) which represents 1/1,000 of the dose capable of eliciting the 
peak eosinophil chemotactic response (Fig.  1 and 2).  Even 10  -r' M  tetrapeptide 
resulted in  substantial  deactivation.  Cross-deactivation by pretreatment  with 
synthetic tetrapeptides was dose and time related  (Fig. 4).  Levels of 10  -12 M  of 
either tetrapeptide did not decrease eosinophil responsiveness to C5a, and corn- 1428  FUNCTIONAL  STRUCTURAL  DETERMINANTS  OF  ECF-A  TETRAPEPTIDES 
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FIG.  3.  Deactivation by synthetic tetrapeptides of eosinophils as assessed by their chemo- 
tactic response to Val-Gly-Ser-Glu. Values shown are the mean percent of control response 
_+ 1 SD  for three experiments with  varying periods  of exposure  of eosinophils  to the 
deactivating tetrapeptide. The three donors exhibited  26, 43, and 59% eosinophilia. The 
control responses  to 10  -7 M valyl-tetrapeptide of these eosinophils ai~r treatment with 
buffer alone were 13.8, 15.1, and 20.3 net eos/hpf, respectively; each control response was set 
at 100%. 
plete deactivation was only found with the 10  -8 M concentration. In experiments 
not shown,  the leucyl-tetrapeptide analogue deactivated and cross-deactivated 
eosinophils with dose-response and time-course relationships  similar  to those 
observed for the alanyl- and valyl-tetrapeptides. The deactivating activity of the 
phenylalanyl-tetrapeptide was minimally evident at 10  -7 M, and at 10  -6 M was 
comparable to 10  -~° M  alanyl-tetrapeptide. 
Modulation of Eosinophil Responses to ECF-A Tetrapeptides by Substituent 
Tripeptides  and Amide Derivatives of Hydrophobic Amino Acids.  The NH2- 
terminal tripeptide, Val-Gly-Ser, and the COOH-terminal tripeptide,  Gly-Ser- 
Glu,  both of which  are only marginally chemotactic,  were analyzed for their 
effects on the eosinophil chemotactic response to the intact tetrapeptide,  Val- 
Gly-Ser-Glu.  In  this  study,  the  tripeptide  was  introduced  into  the  stimulus 
compartment  with  the  tetrapeptide,  added  to  the  cell  compartment  of the 
chemotactic  chamber,  or  preincubated  with  the  eosinophils  followed by  cell 
washing  before an  analysis  of the  chemotactic  response.  The  NH2-terminal 
tripeptide  inhibited  the  chemotaxis  of eosinophils  in  a  dose-related  fashion 
either when present with the stimulus or the cells (Fig. 5). When added to the 
10  -7 M tetrapeptide stimulus, Val-Gly-Ser gave 50% inhibition of  the eosinophil 
response at approximately an equimolar concentration, while, when present on 
the cell side of the chamber,  10  -7 M  Val-Gly-Ser gave 75-80% inhibition.  The 
inhibitory effect of Val-Gly-Ser on the eosinophil was reversed when the cells 
were washed before their response to the tetrapeptide was assayed. The COOH- E.  J.  GOETZL  AND  K.  F.  AUSTEN  1429 
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FIo.  4.  Deactivation by synthetic tetrapeptides of eosinophils as assessed by their chemo- 
tactic response to C5a. Values shown are the mean percent of control responsiveness ± 1 SD 
for three experiments with varying periods of exposure of eosinophils to the deactivating 
tetrapeptide. The three donors exhibited 26, 43, and 59% eosinophilia. The control responses 
to C5a,  at a  concentration derived from 2.5 ~g equivalent of C5/ml,  of these eosinophils 
treated throughout with buffer were  14.9,  16.5,  and  18.8 net eos/hpf,  respectively;  each 
control response was set at 100%. 
terminal tripeptide, Gly-Ser-Glu, was ineffective when a  10  -7 M concentration 
was mixed with an equimolar quantity of valyl-tetrapeptide stimulus. On the 
other hand,  this concentration gave 75%  inhibition when present in the cell 
compartment,  and  the  inhibitory effect of Gly-Ser-Glu was  not reversed by 
washing the cells. The expression of the NH2-terminal tripeptide effect from the 
stimulus side and its reversibility suggests competition with the chemotactic 
factor.  In contrast,  the  irreversible inhibitory action of the  COOH-terminal 
tripeptide after its interaction with the cell and its failure to act as efficiently 
from the stimulus  side  of the compartment is  compatible  with  cell-directed 
suppression. 
The  capacity of 10  -7  M  NH2-terminal  and  COOH-terminal  tripeptides  to 
suppress the eosinophil response to C5a was examined with the same protocol 
employed above with the valyl-tetrapeptide stimulus.  In two experiments in 
which the NH2-terminal tripeptide was added with the stimulus, there was 47 
and 61% inhibition of the valyl-tetrapeptide effect, but only 18 and 29% inhibi- 
tion of the C5a-stimulated response of the cells. In three experiments, pretreat- 
ment of the eosinophils with  10  -7  M  COOH-terminal  tripeptide followed by 
washing gave  74,  62,  and 48%  inhibition  of their response  to  10  -7  M  valyl- 
tetrapeptide and 71, 53, and 37% inhibition of their response to C5a. Since the 
concentration of C5a utilized was selected for comparable chemotactic activity to 
10  -7 M valyl-tetrapeptide, the relative inability of the NH2-terminal tripeptide 1430  FUNCTIONAL  STRUCTURAL  DETERMINANTS  OF  ECF-A  TETRAPEPTIDES 
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Fro.  5.  Modulation  of eosinophil chemotaxis to  Val-Oly-Ser-Olu by substituent tripep- 
tides. Values depicted are the mean percent of control response of two experiments in which 
the tripeptides were present in the stimulus compartment (©), cell compartment (e),  or 
employed to pretreat the cells followed by washing (Zk). The two donors exhibited 76 and 
89% eosinophilia. The control responses to 10  -7 M valyl-tetrapoptide of eosinophils preincu- 
bated 20 min at 37°C  with buffer alone were  10.5 and 14.3 net eos/hpf; the mean control 
response was set at 100%. 
in  the  stimulus compartment to  inhibit  the  chemotactic activity of C5a  as 
compared to the valyl-tetrapeptide may indicate differences in either the molar 
concentrations of the stimuli or the target cell receptors. 
The amide derivatives of valine, alanine, and leucine, shared with Val-Gly- 
Ser the ability to block the eosinophil chemotactic-stimulating  activity of valyl- 
tetrapeptide (Table I). Approximately 50% inhibition ofeosinophil chemotaxis to 
10  -7 M valyl-tetrapeptide resulted from the addition to the stimulus of 10  -7 M 
leu-amide, or 10  -6 M val-amide or ala-amide. No cell-directed inhibitory activity 
persisted aider the pretreated eosinophils were washed; and thus the inhibitory 
effect  of  the amides, like that of  the NH2-terminal tripeptides, was reversible. 
The hypothesis that the NH2-terminal tripeptides are capable of reversible 
competition with the eosinophilotactic tetrapeptides was further tested by re- 
quiring the tripeptides to protect the target eosinophils from deactivation by the 
intact tetrapeptides. The capacity of 10  -s M  valyl-tetrapeptide to render the 
eosinophils completely unresponsive to a subsequent stimulus of 10  -7 M tetra- 
peptide was prevented in a  dose-related fashion by the presence of the NH2- 
terminal tripeptide with the deactivating stimulus (Table II). The tripeptide at a 
level of 10  -7 M was completely protective, while the equimolar concentration 
achieved approximately 40-50% protection. The specificity of this protection 
toward the tetrapeptide was examined using the COOH-terminal tripeptide as a E. J.  GOETZL  AND  K.  F.  AUSTEN  1431 
TABLE  I 
Modulation by Amides of NH2-Terminal Amino Acids of the Eosinophil Chemotactic 
Activity of Valyl- Tetrapeptide* 
Protocol 
Amide concentration  (M) 
I0  -5  10  -~  10-'  I0  -s 
%  of control response 
Val-amide  Present with stimulus*  21.0  ±  19.7  55.0  -+ 8.7  75,7  ±  14.2  83.5 ±  7.8 
Cell pretreatment§  93.4  _+  7.1  96.2  _+  1.9  86.4  _+  12.3  93.8 ±  8.2 
Ala-amide  Present with stimulus  36.9  ±  21.7  45.3  _+ 31.4  71.4  ±  29.0  88.0  _+  16.3 
Cell pretreatment  -II  86.1  ±  13.4  90.5  _+  11.8  - 
Leu-amide  Present with stimulus  31.3  ±  7.0  41.7  _+ 4.7  58.3  ±  12.9  86.3  ±  17.1 
Cell pretreatment  -  80.9  ±  11.4  91.6  ±  7.2  - 
* Values indicate  the mean percent of  control  response ±i SD for three experiments utilizing 
donors of  86, 37, and 48% peripheral  eosinophilia.  The control  responses of  these  eosinophils  to 
10  -7  M  valyl-tetrapeptide  were 10.1,  12.3,  14.8  net eosinophils  per  hpf,  respectively. 
* Amides were present with the valyl-tetrapeptide  stimulus. 
§ Preincubation of  eosinophils  with amides for  20 min at 37°C,  followed  by washing three times 
before  assessment of  residual  responsiveness to 10  -7  M  valyl-tetrapeptide  stimulus. 
II  Not done. 
TABLE  II 
The Capacity of the NH2-Terminal Tripeptide to Protect Eosinophils from Deactivation 
by the Valyl-Tetrapeptide* 
Pretreatment  factor 
Concentrations of Val-Gly-Ser with 
pretreatment factor 
0  10  -8 M  10-' M  10  -8 M  I0  -" M 
Valyl-tetrapeptide  10  -8 M  -  12.7 
7  COOH-terminal tripeptide 10-  M  54.4 
% of control response 
-$  124.9  39.2 
36.7  28.1  47.6 
-18.2 
* The pretreatment period was 20 min at 37°C, and the eosinophils were washed three times before 
assessing chemotactic responsiveness to 10-' M  valyl-tetrapeptide.  Values are the mean percent 
of control  responses  for  two  experiments  utilizing  donors  of 37  and  86%  peripheral  blood 
eosinophilia. The control responses to 10  -7 M  valyl-tetrapeptide of eosinophils exposed to buffer 
alone were 8.1 and 11.7 net eos/hpf. A  negative value represents suppression below the control 
unstimulated level of migration. 
$ Not done. 
cell-directed  inhibitory factor  (Table  II).  The  NH~-terminal  tripeptide  at  an 
equimolar concentration or at a 10-fold excess afforded no protection against the 
COOH-terminal tripeptide,  indicating that the NH~-terminal tripeptide effect 
was directed  against the interaction with the eosinophil of the NH2-terminal 
portion of the intact tetrapeptide. 
Since the eosinophilotactic tetrapeptides  also elicited directed  migration of 
neutrophils, the inhibitory actions of the NH2- and COOH-terminal tripeptides 
on this response were evaluated. In two experiments with neutrophils purified 
to 98% and eosinophils of 51 and 68% purity, the chemotactic responses were 16.9 1432  FUNCTIONAL  STRUCTURAL  DETERMINANTS  OF  ECF-A  TETRAPEPTIDES 
and 21.4 neutrophils/hpf, and 12.7 and 15.3 eosinophils (eos)/hpf, respectively. 
The NH~-terminal tripeptide added to the stimulus gave 49 and 54% inhibition of 
the response of neutrophils and 53 and 64% inhibition of the response of eosino- 
phils to an equimolar concentration of valyl-tetrapeptide. The COOH-terminal 
tripeptide irreversibly inhibited the neutrophil response by only 33 and 28%, as 
compared to 61 and 74% inhibition of the eosinophil response to 10  -7 M valyl- 
tetrapeptide. 
Eosinophil Chemotactic Activity of Mixtures of Alanyl- and Valyl-Tetrapep- 
tides.  To interpret the eosinophil response to mixtures ofECF-A tetrapeptides, 
it  was essential  to recognize where the molar concentration of any mixture 
would fall on the dose-response curve of an individual tetrapeptide. To examine 
both ends of the dose-response curve, equal increments of the alanyl- or valyl- 
tetrapeptide were added to a minimally or maximally active alanyl-tetrapeptide 
concentration (Fig. 6). The results obtained with each mixture were compared to 
the calculated additive effect of the tetrapeptides assayed separately in order to 
determine whether the mixtures were inhibitory, additive, or synergistic. Using 
a  minimally active quantity of 3  x  10  -8 M  alanyl-tetrapeptide, the first two 
stepwise additions of both peptides were essentially additive, while the final 10- 
fold addition yielded a  mixture which was less effective than the calculated 
additive response.  When a  10  -7 M  concentration of alanyl-tetrapeptide which 
yielded a peak response was employed, each increment of either peptide gave a 
mixture that was less effective than the additive sum of  their individual actions. 
The fact that the combinations were either additive or inhibitory indicates" that 
there was no cooperative effect among receptors occupied by these tetrapeptides. 
Discussion 
The capacity of  the tetrapeptides of ECF-A, Ala/Val-Gly-Ser-Glu, to stimulate 
directed migration  of eosinophils  in  vitro  can  be  modified by  deletions  or 
substitutions of single amino acid residues and modulated by nonchemotactic 
substituent peptides. Substitution of  the NH2-terminal residue led to alterations 
in potency and maximum activity which are defined, respectively, as the con- 
centration of chemotactic peptide eliciting a  peak eosinophil chemotactic re- 
sponse  and the magnitude of that response.  The leucyl-tetrapeptide was the 
most potent tetrapeptide exhibiting peak activity at 10  -8 M-10  -7 M, while peak 
activity for the ECF-A valyl- and alanyl-tetrapeptides was achieved at 10  -7 M 
and 10  -6 M, respectively (Fig.  1). In contrast, the introduction of a  six-carbon 
aromatic ring, employing phenylalanine as the NH2-terminal residue, produced 
a  tetrapeptide eliciting a  peak eosinophil chemotactic activity at 10  -4 M.  The 
magnitude of the eosinophil response was not related to potency in that the 
phenylalanyl-tetrapeptide  elicited  the  greatest  maximum response  and  the 
leucyl.tetrapeptide the least.  Inversion of the order of the internal residues, 
glycine and serine, did not lead to an alteration of  potency or maximum activity 
of the synthetic valyl- or leucyl-tetrapeptides (Fig. 2). However, elimination of 
the glycine residue from either tetrapeptide, producing condensed tripeptides of 
the  sequence Val/Leu-Ser-Glu,  was  associated  with  a  distinct  reduction  in 
potency and a modest decrease in peak activity. Thus, the nature of the NH2- 
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FIG.  6.  Eosinophi] chemotactic activity of mixtures ofalany]- and va]y]-tetrapeptides.  The 
response to the alanyl-tetrapeptide  alone and to the mixtures  is depicted by the height of 
each cross-hatched  bar; a]] values are the mean of two studies.  The fixed concentration  of 
the alany]-tetrapeptide  was 3  x  10  -s M  in the left-hand  series and 10  -7 M  in the right  hand 
series. Each black bar depicts the mean calculated sum of the individual responses to the 
fixed dose of alanyl-tetrapeptide and the varying concentrations of valyl- or alanyl-tetra- 
peptides.  The experimental response to the varying concentrations of the alanyl- or valyl- 
tetrapeptide alone may be derived by subtracting the response to the fixed dose of alanyl- 
tetrapeptide from the calculated sum of the individual responses. 
influences both  the  potency and  maximum activity  of the  eosinophilotactic 
peptides. 
The exposure of eosinophils to the alanyl- and valyl-tetrapeptides, followed by 
washing the treated cells, markedly reduced their chemotactic responsiveness to 
the valyl-tetrapeptide (Fig. 3) and to Cba (Fig. 4). This time- and dose-related 
irreversible process, termed functional deactivation, has been previously de- 
scribed  for  human neutrophils  (19) and  eosinophils  (20), as  well  as  rabbit 
neutrophils (21,  22). Deactivation of human neutrophils by C5a obtained by 
tryptic digestion of C5 and by partially purified kallikrein generally has not 
been detected at factor levels less than 1/10 the minimal chemotactic concentra- 
tion (19, 23), while human eosinophil deactivation by partially purified human 
lung ECF-A was  observed after  30 min with as little  as  1/160 the minimal 
chemotactic concentration  (20). Deactivation of eosinophils by the  synthetic 
peptides was essentially complete afLer 20 min at a concentration 1/100 and aider 
40-100  min at a concentration 1/10,000 the minimal chemotactic dose (Fig. 3). 
The extent of deactivation at a given time and dose of tetrapeptide was greater 
to  a  chemotactic stimulus of valyl-tetrapeptide than  to  a  heterologous Cba 
stimulus (Fig. 3 and 4). Whether the high degree of susceptibility of the human 
eosinophil to deactivation by the tetrapeptides is a unique feature of  this class of 
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analyses utilizing other leukocyte types and completely purified or synthetic 
chemotactic factors. 
The high<lose inhibition observed with ECF-A tetrapeptides, the NH2-termi- 
nal-substituted analogues, and the condensed tripeptides lacking an internal 
glycine (Fig.  1 and 2) is a phenomenon shared with some other small peptide 
chemotactic factors acting on rabbit neutrophils (24, 25). When tetrapeptides are 
mixed at  concentrations at  which each  alone  is  well  within the  ascending 
portion of its dose-response curve, the response to mixtures is approximately the 
sum of the responses to each component (Fig. 6). At higher peptide concentra- 
tions, the response to mixtures may be less than additive because the combined 
molar concentrations fall on an inhibitory portion of  the dose-response curves for 
ECF-A tetrapeptides. This interpretation presumes that the two eosinophilotac- 
tic tetrapeptides are independently recognized by the target cells, and that the 
effect  of their  combined molar  concentrations is  similar  to  what  would be 
observed with a comparable molar concentration of either alone. 
The  substituent  NH2-terminal  and  COOH-terminal  synthetic tripeptides, 
which lack significant chemotactic activity, are capable of inhibiting the eosino- 
phil chemotactic response to the intact stimulus. The NH2-terminal tripeptide, 
Val-Gly-Ser, gave a dose-response inhibition when present on the stimulus side 
with 10  -7 M valyl-tetrapeptide which was 50-60% at equimolar concentrations 
(Fig.  5).  The inhibition by Val-Gly-Ser was somewhat greater when present 
with the cells as compared to the stimulus side, but the effect on the cells was 
reversed by washing. The inhibitory action of the NH2-terminal tripeptide when 
present on the stimulus side and the reversibility of its inhibitory effects when 
present on the cell side suggest a direct competition with the eosinophilotactic 
tetrapeptide at  the eosinophil surface.  This concept is  substantiated by the 
capacity of the NH2-terminal tripeptide to protect the eosinophil from deactiva- 
tion by the valyl-tetrapeptide with 40-50%  protection at equimolar concentra- 
tions (Table II). The entire tripeptide was not required for effective competition 
with  the  valyl-tetrapeptide  in  that  amide  derivatives  of the  NH2-terminal 
residues, which were devoid of chemotactic and irreversible cell-directed inhibi- 
tory activities, gave dose-response inhibition when present on the stimulus side 
(Table I).  50%  inhibition by the amide derivatives required a  10-fold higher 
concentration than for the corresponding  tripeptide which implies that the seryl- 
residue  enhances the  interaction  of the  tripeptide  with  the  eosinophil and 
potentiates its competitive capability. Further, the inhibitory action of  the NH2- 
terminal  tripeptide  could  also  be  observed  on  the  chemotactic response  of 
neutrophils and equimolar concentrations again reduced the response to 10  -7 M 
valyl-tetrapeptide by  approximately 50%. The  capacity of the NH2-terminal 
tripeptide  to  inhibit  the  chemotactic stimulation  of neutrophils as  well  as 
eosinophils and to prevent deactivation of eosinophils by the intact tetrapeptide 
indicates a stimulus-specific competitive action. 
The COOH-terminal tripeptide irreversibly suppresses the eosinophil chemo- 
tactic response to 10  -7 M  valyl-tetrapeptide in a  dose-response manner. Full 
suppression at 20 min required COOH-terminal tripeptide concentrations of 10  -6 
M-10  -5 M  (Fig.  5) which are more than 10,000-fold  higher than the doses of 
intact  tetrapeptide required for complete deactivation  (Fig.  3).  The  COOH- E.  J.  GOETZL  AND  K.  F.  AUSTEN  1435 
terminal tripeptide did not compete with the tetrapeptide from the stimulus side 
(Fig.  5).  Further,  the  cell-directed inhibitory action of the  COOH-terminal 
tripeptide, in contrast to that of the intact tetrapeptide, was not blocked by the 
NH2-terminal tripeptide (Table II). 
A  hypothetical model is  proposed for  a  tetrapoptide chemotactic receptor 
based on the functional data derived from the eesinophilotactic activity of the 
structural analogues of the ECF-A tetrapeptides and the modulation of tetra- 
peptide activity by substituent sequences. The chemotactic activity of the tetra- 
peptide is  dependent on both the  hydrophobic NH2-terminal  residue,  which 
interacts  with  a  hydrophobic domain  in  the  chemotactic receptor,  and  the 
highly-charged COOH-terminal residue which is presumed to initiate eosino- 
phil movement by perturbing a polar domain in the same receptor. The spatial 
requirement for  effective  interaction  with  both  domains in  the  receptor  is 
revealed by the lower potency and activity of the condensed tripeptides lacking 
glycine. The 10-fold greater potency of NH2-terminal tripeptide compared to the 
amide derivatives of NHs-terminal  amino acids  in  reversibly inhibiting the 
intact tetrapeptides suggests a  role for serine in binding to a  portion of the 
receptor, possibly by hydrogen bonding. The COOH-terminal substituent tri- 
peptide irreversibly suppresses eosinophil chemotaxis by a cell-directed action 
possibly reflecting its capacity to perturb the polar domain; this effect, resem- 
bling deactivation, requires higher concentrations than needed for deactivation 
by the tetrapeptide. 
Summary 
The acidic tetrapeptides ofECF-A, Ala/Val-Gly-Ser-Glu, exhibit peak in vitro 
chemotactic activity for human eosinophils at concentrations of 3  ×  10  -8 M to 
10  -6 M, and rapidly deactivate eosinophils to homologous and other stimuli at 
concentrations as low as 10  -1° M. The analogue Leu-Gly-Ser-Glu reaches peak 
activity at 10  -s M-10  -7 M, while Phe-Gly-Ser-Glu requires 10  -4 M to elicit a peak 
response. Although inversion of  the order ofglycine and serine does not alter the 
eosinophil chemotactic activity of  the tetrapeptides, deletion ofglycine increases 
by 10-fold the concentration required for peak chemotactic activity, indicating 
the critical nature of the spacing between NH2- and COOH-terminal residues. 
The substituent COOH-terminal tripeptide, which is only marginally chemotac- 
tic, irreversibly suppresses eosinophil chemotactic responsiveness at a concen- 
tration 10,000-fold higher than concentrations necessary for deactivation by the 
intact tetrapeptide. The high concentration of tripeptide required for this cell- 
directed effect, which is assumed to be analogous to deactivation, is attributed to 
the absence of  the NH2-terminal residue which would facilitate effective interac- 
tion with the eosinophil. A substituent NH2-terminal tripeptide and amides of 
the NH2-terminal amino acids, which are devoid of chemotactic and deactivat- 
ing activities, reversibly inhibit the tetrapeptide stimulus in a  dose-response 
fashion. The additional finding that the NH2-terminal tripeptide protects the 
eosinophil from deactivation by the intact tetrapeptide confirms that the com- 
petitive interaction is stimulus specific. 
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